OBSOLETE: Oligoarticular juvenile idiopathic arthritis without anti-nuclear antibodies

Oligoarticular juvenile idiopathic arthritis (JIA) without anti-nuclear antibodies (ANA) was a subclassification used within the broader category of oligoarticular JIA, referring to children who develop chronic joint inflammation (arthritis) affecting four or fewer joints during the first six months of disease but who test negative for anti-nuclear antibodies. This entry is now marked as OBSOLETE in the Orphanet classification, as evolving classification systems for juvenile idiopathic arthritis have moved away from subdividing oligoarticular JIA based solely on ANA status in this manner. The condition primarily affects the musculoskeletal system, with symptoms including joint swelling, pain, stiffness (particularly in the morning), and reduced range of motion, most commonly involving large joints such as the knees and ankles. In the broader context of oligoarticular JIA, ANA-negative patients were historically noted to have a somewhat different risk profile compared to ANA-positive patients, particularly regarding the risk of chronic anterior uveitis (eye inflammation), which is more strongly associated with ANA positivity. However, all children with oligoarticular JIA require regular ophthalmologic screening regardless of ANA status. Treatment typically includes nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroid injections, and in refractory cases, disease-modifying antirheumatic drugs (DMARDs) such as methotrexate or biologic agents. Because this specific Orphanet entry is obsolete, patients and clinicians are directed to the broader category of oligoarticular juvenile idiopathic arthritis for current classification and management guidance.

Common questions about OBSOLETE: Oligoarticular juvenile idiopathic arthritis without anti-nuclear antibodies